Formation of platinum-DNA adducts in pediatric patients receiving carboplatin

Margaret E. Tonda, Daryl J. Murry, John H. Rodman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Study Objective. To determine the extent of platinum-DNA (Pt-DNA) adduct formation in peripheral white blood cells of children with cancer. Design. Prospective study. Setting. Pediatric research hospital. Patients. Twenty- seven children receiving carboplatin as part of therapy as defined by clinical research protocols. Interventions. Patients received various dosages of carboplatin over 1, 3, or 24 hours as a primary component of combination chemotherapy for pediatric solid tumors, brain tumors, or large cell lymphoma. Measurements and Main Results. The Pt-DNA adducts were detectable in 10 (37%) of 27 patients. The median value was 3.4 fmol Pt/μg DNA (range 1.7-31.2 fmol) in patients with measurable values. Conclusion. The Pt-DNA adducts were detected less frequently in pediatric patients than reported in adults. Variables that influenced their detection were higher carboplatin dosages or systemic exposure and short (1-3 hrs) versus prolonged (24 hrs) infusions.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalPharmacotherapy
Volume16
Issue number4
StatePublished - Jul 1996

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Formation of platinum-DNA adducts in pediatric patients receiving carboplatin'. Together they form a unique fingerprint.

Cite this